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Q&APositive GradientsThe new associate vice chancellor of computational heath sciences at the University of California San Diego
reflects on the coming era of big data in medicine.Jill Mesirov is heading west, quite literally
from Boston to San Diego and figuratively
to the frontier, vast with potential, at the
interfaces of biology, technology, data
science, and healthcare. Cell Systems
spoke with her as she wrapped up her
tenure as associate director and chief
informatics officer at the Broad Institute.‘‘.to do great computational biomedical research, you really
have to understand the domain.’’In this edited interview, Mesirov speaks
about uniting communities through
biomedical rather than analytical chal-
lenges and four lessons for the computa-
tional health sciences.
Cell Systems: Why San Diego?
Jill Mesirov: First of all, I spent a year on
sabbatical there many years ago, and I
find San Diego to be a young, energetic,
growing place. I’m a mathematician by
training, and there are a lot of places
that have positive gradients, but I think
UCSD is a place with a large positive sec-
ond derivative. It’s really accelerating.
And you can play tennis and golf outside
in January. What’s not to like?
The other thing I think that’s great about
UCSD is that it’s not just an academic
medical center, but it’s got this wonderful
combination of a great medical school
with associated hospitals, a terrific engi-
neering school, and a large supercom-
puter center. Not so many places have
that combination. It’s also a very collabo-
rative place.
Are there particular groups you
hope to collaborate with?
It’s interesting that you bring that up
because UCSD has just announced a
search to fill eight tenure track interdisci-
plinary positions that are joint appoint-
ments in health sciences and the Jacobs
School of Engineering. It shows how
serious the University’s commitment is
to its initiative in precision medicine to2 Cell Systems 1, July 29, 2015 ª2015 Elseviimprove patient care. This search is tar-
geting experts in both big data and
biomedical research. I’m excited to
participate on the search committee
because the field is turning out these
new kinds of scientists with strengths
in biology and computation or engineer-
ing, and I think those are the peoplewho are going to move things forward.
We’re looking for people who have that
collaborative spirit and that interdisci-
plinary drive to advance research as a
group but also develop interactions
across the campus.
Why shift toward health sciences
now?
We’re acquiring all these big biomedical
datasets, and there are all these new
technologies, both laboratory technolo-
gies and computational methods, plus
the momentum of what people call preci-
sion medicine or individualized health-
care. It’s just a great time to pull it all
together.
Not just in genomics but alsometabolo-
mics, the whole microbiome effort, prote-
omics is scaling up, imaging, the availabil-
ity of pulling together phenotype data and
clinical data from electronic health re-
cords. There’s no comparison between
the amount and variety of data that we
have available to us now with what we
had 20 years ago.
This makes for an incredible opportu-
nity for people who have the computa-
tional skills and who are driven to make
an impact on human health. It’s not
just about computer science. It’s about
improving the way we treat patients.
That’s very real and exciting to me.
Talented and smart students are seeing
what’s happening in this area, and they
realize, ‘‘I want to be there. I want to be
part of this.’’er Inc.What if you’re not a new trainee
starting your career?
I don’t have a magic roadmap for this. My
experience has been with moving from
analytic fields into biomedical research.
The people who are successful are the
ones who are really driven by the prob-
lems and by the biology or the biomedical
challenge, not just the analytic chal-
lenges. For me, the analytic challenges
came with it, of course, from the develop-
ment of new methodologies and so on,
but it was always with that end goal of
the application.
Tell me more about uniting
communities through shared
biomedical challenges?
If you can pull together a group of inves-
tigators with similar scientific goals, you
get more out of that than just the sum of
the parts. It’s not linear—so whether
they’re working all on the same project
or just in the same area, then you have
this sharing of ideas, of methods and
technologies, and that’s really key. I think
that there may be ways that we can
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There is a growing community at UCSD,
for example, around the microbiome.
These communities don’t happen by acci-
dent but they do bubble up a bit. You get
people together and they share ideas,
and then you find that you’re all thinking
about the same thing, and that you’re all
facing the same challenge, and then that
challenge becomes a goal for you as a
broader group. This process is organic
so it’s hard for me to predict what the
areaswill be, say, in thenext 10 years. Pre-
cision medicine is a likely one, but it will
depend somewhat on the interests and
scientific thrusts of who is hired.
Are you tracking particular
computational challenges?
One is visualization. How do we visualize
all this big clinical data, not just genomic
data but other omic data and other clinical
data and to make that data interpretable
and usable clinically. I think that’s a real
challenge, and it’s another reason that
I’m looking forward to being at a medical
center because there’s a great opportu-
nity for computational biologists and
clinicians to sit together as patients’ data
are discussed. This would have a huge
impact for visualization work.
What will be the keys to making big
data useful to clinicians through
software?
The way you develop good accessible
friendly software, which has always been
a religion ofmine inmanyways, is by living
in the community that is going to use the
software. What excites me about being
in a place like UCSD is being able to link
up with people who can help design the
entire workflow of interactions betweenclinicians, patients, and the software and
data. You have to really learn the domain,
learn to speak its language, and under-
stand people’s thought processes.
There are also all kinds of regulatory
issues that will need to be addressed. It
may be that one develops the prototype
by working closely with clinicians and
then finds some way to pass it off to an
organization that’s going to make it more
commercially viable and satisfy all the
regulatory requirements.
Reflect on your 18 years at the
Whitehead Genome Center and the
Broad Institute. How have things
changed?
When I came to the Whitehead Genome
Center, there were four people in IT and
a handful of bioinformatic analysts. The
servers were people’s desktop machines.
The storage was a wire rack in the hallway
of 2 gigabyte external disk drives. In the
summer, the sun would shine in the win-
dow, and the disks would all go down
because they would overheat. Today at
the Broad, there are hundreds of people
in computational biology and bioinformat-
ics, which has permeated every single
aspect of the organization. I’ve seen peo-
ple who’ve been there a long time grow as
scientists and become independent re-
searchers. That’s very satisfying to me.
What are a few lessons you’ve
learned?
First, I’ve learned this lesson, that if you’re
going to do great computational biomed-
ical research, you really have to under-
stand the domain.
Second, this idea that you can gather a
group of people together with similar sci-
entific interests that becomes more than
the sum of the parts.Cell SystThird, you can generate some very
interesting hypotheses by mining big
data, but you have to go back to the lab
or the clinic to validate those findings.
Without both parts of the process, both
the computational and the experimental
or the computational and the clinical,
you haven’t really pushed the work for-
ward. You have to have people with both
sets of skills, and sometimes those are
different people and more and more, it
can be the same person, but that’s how
you make it real.
Finally, we have this wealth of data, and
we need to empower everyone to use it
well. That’s this whole idea of making
accessible, usable software so that peo-
ple have something that helps them do
the things that are more straightforward,
the analyses we now know how to do
well, so that they can provide additional
value where their expertise is.
Final thoughts?
The other thing I’m taking with me is
that I have made such incredible relation-
ships in the Boston area. People who
have taught me things, people who’ve
collaborated with me on projects, scien-
tists and friends that I’ll have for the
rest of my life, and that’s a really
important thing to me. You spend
18 years in a community, you do that
for a reason and a lot of that reason is
the people. The people have been great,
and I value every one of them that I’ve
interacted with, and moving forward, I
strongly believe that I will build that
same network of collaborators and
friends at UCSD.
And are you going to start surfing?
Not likely, tennis and golf are enough
for me!
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